GR1001065B - Πολυπεπτιδικα αναλογα της απολιποπρωτεινης ε,διαγνωστικα συστηματα και μεθοδοι χρησιμοποιησεως αυτων. - Google Patents

Πολυπεπτιδικα αναλογα της απολιποπρωτεινης ε,διαγνωστικα συστηματα και μεθοδοι χρησιμοποιησεως αυτων.

Info

Publication number
GR1001065B
GR1001065B GR900100621A GR900100621A GR1001065B GR 1001065 B GR1001065 B GR 1001065B GR 900100621 A GR900100621 A GR 900100621A GR 900100621 A GR900100621 A GR 900100621A GR 1001065 B GR1001065 B GR 1001065B
Authority
GR
Greece
Prior art keywords
polypeptide
analogs
methods
diagnostic systems
apolipoprotein
Prior art date
Application number
GR900100621A
Other languages
English (en)
Other versions
GR900100621A (en
Inventor
Linda K Curtiss
Cheryl A Dyer
Richard Smith
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/395,732 external-priority patent/US5177189A/en
Priority claimed from US07/485,158 external-priority patent/US5182364A/en
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of GR900100621A publication Critical patent/GR900100621A/el
Publication of GR1001065B publication Critical patent/GR1001065B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Connection Of Plates (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεσις αφορά εις πολυμερές πολυπεπτίδιον δυνάμενον να μιμηθεί την ικανότητα της apo E να προκαλεί διαφοροποιημένην κυτταρικήν λειτουργίαν. Η επαναλαμβανόμενη μονάς του πολυπεπτιδίου έχει αλληλουχίαν ριζών αμινοξέων αντιστοιχούσαν εις την αντιπροσωπευομένην υπό του τύπου LRKLRKRLLRDADDL. Θεωρείται επίσης μέθοδος θεραπείας της υπεχοληστεριναιμίας εις ασθενή, περιλαμβάνουσα την χορήγησιν εις τον ασθενή μιας υποβιβαζούσης την εις το πλάσμα συγκέντρωσιν της LDL ποσότητος του πολυπεπτιδίου. Περιγράφεται επίσης η χρήσις του πολυπεπτιδίου εις την παρασκευήν διαγνωστικών αντισωμάτων και η χρήσις αυτών εις διαγνωστικά συστήματα και μεθόδους ανιχνεύσεως αντιγόνων apo E εις αγγειακά υγρά του σώματος. ω
GR900100621A 1989-08-18 1990-08-17 Πολυπεπτιδικα αναλογα της απολιποπρωτεινης ε,διαγνωστικα συστηματα και μεθοδοι χρησιμοποιησεως αυτων. GR1001065B (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/395,732 US5177189A (en) 1989-08-18 1989-08-18 Polypeptide analogs of Apolipoprotein E
US07/485,158 US5182364A (en) 1990-02-26 1990-02-26 Polypeptide analogs of apolipoprotein E
US07/540,363 US5168045A (en) 1989-08-18 1990-06-18 Diagnostic systems and methods using polypeptide analogs of apolipoprotein e

Publications (2)

Publication Number Publication Date
GR900100621A GR900100621A (en) 1991-12-30
GR1001065B true GR1001065B (el) 1993-04-28

Family

ID=27410184

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100621A GR1001065B (el) 1989-08-18 1990-08-17 Πολυπεπτιδικα αναλογα της απολιποπρωτεινης ε,διαγνωστικα συστηματα και μεθοδοι χρησιμοποιησεως αυτων.

Country Status (9)

Country Link
US (1) US5168045A (el)
EP (1) EP0487629A1 (el)
JP (1) JPH05501400A (el)
AU (1) AU648991B2 (el)
FI (1) FI920670A0 (el)
GR (1) GR1001065B (el)
IE (1) IE902992A1 (el)
PT (1) PT95030A (el)
WO (1) WO1991002751A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
CA2137814A1 (en) * 1992-06-12 1993-12-23 Maryvonne Rosseneu New peptides and proteins, process for their preparation and their use as cholesterol acceptors
WO1994004178A1 (en) * 1992-08-12 1994-03-03 Bio-Technology General Corp. Method of inhibiting cell proliferation using apolipoprotein e
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US20030077641A1 (en) * 1998-03-11 2003-04-24 Laskowitz Daniel T. Methods of suppressing microglial activation and systemic inflammatory responses
US7205280B2 (en) * 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
EA037404B1 (ru) 2008-11-10 2021-03-24 Арбутус Биофарма Корпорэйшн Липиды и композиции для доставки лекарственных средств
ITTO20080894A1 (it) * 2008-12-02 2010-06-03 Bioindustry Park Del Canavese S P A Uso dell'aptoglobina, peptidi leganti l'aptoglobina, polimeri contenenti gli stessi e loro uso
CA3036963A1 (en) 2009-01-29 2010-08-05 Arbutus Biopharma Corporation Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
NZ596186A (en) 2009-05-05 2014-03-28 Alnylam Pharmaceuticals Inc Lipid compositions
NZ712719A (en) 2009-06-10 2017-03-31 Arbutus Biopharma Corp Improved lipid formulation
BR112012000908A2 (pt) 2009-07-14 2019-09-24 Mayo Found Medical Education & Res liberação de agentes ativos através da barreira hematoencefálica mediada por peptídeo em associação não covalente
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
CA2783372C (en) 2009-12-07 2019-07-16 Muthiah Manoharan Compositions for nucleic acid delivery
WO2011075656A1 (en) 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
JP2013527856A (ja) 2010-05-12 2013-07-04 プロチバ バイオセラピューティクス インコーポレイティッド 陽イオン性脂質およびその使用方法
EP2575764B1 (en) 2010-06-03 2017-04-19 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP3202760B1 (en) 2011-01-11 2019-08-21 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
AU2012315965A1 (en) 2011-09-27 2014-04-03 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted PEGylated lipids
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
CN112375138B (zh) * 2020-11-13 2022-12-13 中元汇吉生物技术股份有限公司 一种重组载脂蛋白e和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483793A (en) * 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US4677057A (en) * 1985-03-11 1987-06-30 Scripps Clinic And Research Foundation Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
SE448324B (sv) * 1985-09-27 1987-02-09 Pharmacia Ab Sett vid immunkemisk bestemning av lipoproteiner och apolipoproteiner
US4828986A (en) * 1986-09-29 1989-05-09 Scripps Clinic And Research Foundation Assay method and diagnostic system for determining the ratio of APO B-100 to APO A-I in a blood sample
ZA884504B (en) * 1987-06-29 1989-03-29 Merrell Dow Pharma Immunosuppressant peptides

Also Published As

Publication number Publication date
JPH05501400A (ja) 1993-03-18
US5168045A (en) 1992-12-01
EP0487629A1 (en) 1992-06-03
IE902992A1 (en) 1991-02-27
WO1991002751A1 (en) 1991-03-07
PT95030A (pt) 1991-04-18
FI920670A0 (fi) 1992-02-17
GR900100621A (en) 1991-12-30
AU6337090A (en) 1991-04-03
AU648991B2 (en) 1994-05-12

Similar Documents

Publication Publication Date Title
GR1001065B (el) Πολυπεπτιδικα αναλογα της απολιποπρωτεινης ε,διαγνωστικα συστηματα και μεθοδοι χρησιμοποιησεως αυτων.
ATE295176T1 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
DE59107192D1 (de) Medizinische Vorrichtung zur Erzeugung eines alternierenden Volumenstroms für den Antrieb von implantierbaren Blutpumpen
EP0245362A4 (en) SYNTHETIC PEPTIDES AND THEIR USE FOR DIAGNOSIS AND VACCINATION AGAINST AIDS AND ITS ASSOCIATED COMPLEX.
GR910100087A (el) Πολυπεπτιδικα αναλογα της απολιποπρωτεινης ε.
DE68928130T2 (de) Synthetische vom HIV-GP120-env-Protein abgeleitete Peptide und ihre Anwendung
DK0497915T3 (da) hPTH-fragment(1-37), fremstilling heraf, lægemiddel, som indeholder det, samt anvendelse heraf
DE3877154D1 (de) Verfahren zur verhinderung der bildung von blutgerinnseln in dem extrakorporalen kreislauf eines dialyseapparats sowie dazu geeignetes mittel.
CA2123786A1 (en) Method of treating viral infections with c-reactive protein
DE3782771D1 (de) Gegen pseudomonas aeruginosa infektionen wirksame praeparationen und verfahren zu ihrer herstellung.
ATE105086T1 (de) Diagnostisches mittel und verfahren zur bestimmung von apolipoprotein b.
CA1286989C (en) Immunoamplifiers and related compositions
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
DE69028561T2 (de) Immunoassay zum Nachweis von Antikörpern gegen HIV
AU672430B2 (en) Antithrombin III preparation
Wallas et al. Isolation of a Kell‐reactive protein from red cell membranes
Griffith et al. Preparation of high specific activity plasma AHF by anti-FVIIIC immunoaffinity chromatography
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
Brettler et al. Factor VIII: C purified from plasma via monoclonal antibodies: human studies
ATE80306T1 (de) Mittel zur absorptionsverbesserung von proteinen.
Nilsson et al. Tolerance induction in high-responding hemophiliacs with F VIII antibodies by means of combined treatment with IgG, cyclophosphamide and F VIII
Sinden Identification of specific antibodies prepared against purified immobilization antigens of Paramecium aurelia
Mackie et al. The Functional Heterogeneity Of Clinical FVIII Concentrates
Cunningham-Rundles et al. CHANGES IN ANTI-CARD10LIPIN ANTIBODY TITER IN SERA OF I TP PATIENTS AFTER TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN